Does Methotrexate Worsen Respiratory Issues?
Methotrexate, a common treatment for rheumatoid arthritis, psoriasis, and some cancers, carries a risk of pulmonary toxicity that can aggravate or cause respiratory problems. This occurs in 1-10% of patients, typically as methotrexate-induced pneumonitis—a hypersensitivity reaction leading to cough, shortness of breath, fever, and low oxygen levels. Symptoms often appear within months of starting therapy but can emerge anytime. Risk rises with higher doses, older age, diabetes, rheumatoid lung disease, or concurrent use of drugs like NSAIDs or trimethoprim-sulfamethoxazole.[1][2]
How Does Methotrexate Affect the Lungs?
It triggers inflammation and fibrosis in lung tissue via immune-mediated damage, distinct from infections or heart failure. Hypoxemia and bilateral infiltrates show on chest imaging. Acute cases mimic pneumonia; chronic ones cause progressive scarring. Discontinuing the drug usually resolves symptoms, but severe cases require steroids or hospitalization.[1][3]
Who Is Most at Risk?
Patients with pre-existing lung conditions like rheumatoid arthritis-associated interstitial lung disease (RA-ILD) face higher odds—up to 17% incidence. Smoking, hypoalbuminemia, and renal impairment also increase vulnerability. Low-dose weekly regimens (for autoimmune diseases) pose lower risk than high-dose cancer protocols.[2][4]
What Symptoms Should You Watch For?
Early signs include dry cough, dyspnea on exertion, and fatigue. Fever or weight loss may accompany. If these develop, imaging (HRCT) and lung function tests confirm diagnosis, ruling out infection via bronchoalveolar lavage.[1][3]
How Is It Diagnosed and Treated?
Diagnosis relies on clinical history, excluding alternatives like infection or heart issues. Treatment starts with immediate methotrexate cessation; most improve within weeks. Corticosteroids speed recovery in moderate-severe cases, with rare fatalities (1-5% of toxicity events).[2][5]
Can You Use Methotrexate with Lung Disease?
Guidelines recommend caution or avoidance in active interstitial lung disease. Baseline pulmonary function tests and monitoring every 3-6 months help. Alternatives like leflunomide or biologics (e.g., rituximab) may suit high-risk patients better.[4][6]
How Common Is This Compared to Other Drugs?
Less frequent than with drugs like amiodarone (10-17%) but more tied to rheumatoid populations. Folic acid supplementation reduces overall toxicity without fully preventing lung effects.[1][2]
Sources
[1]: UpToDate: Methotrexate pulmonary toxicity
[2]: American College of Rheumatology: Methotrexate guidelines
[3]: New England Journal of Medicine: Drug-induced lung disease
[4]: Chest Journal: Methotrexate in RA-ILD
[5]: PubMed: Methotrexate pneumonitis review
[6]: EULAR recommendations for RA management